4 citations,
May 2019 in “Asian Journal of Pharmaceutical Sciences” Created tablet similar to Avodart using γ-cyclodextrin and solubilizers.
8 citations,
January 2021 in “Pharmaceutics” Nanoporous silica entrapped lipid-drug complexes significantly improve the solubility and absorption of drugs that don't dissolve well in water.
August 2010 in “The Journal of urology/The journal of urology” Male pattern baldness may be linked to prostate cancer risk.
408 citations,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
343 citations,
October 2015 in “Endocrine Practice” The guide recommends specific methods for diagnosing PCOS and various treatments for its symptoms, while considering the health impacts on adolescents.
339 citations,
February 2014 in “Journal of The American Academy of Dermatology” Most patients with frontal fibrosing alopecia are postmenopausal women, and treatments like finasteride and dutasteride can improve or stabilize the condition.
223 citations,
December 2010 in “The Journal of Sexual Medicine” Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.
195 citations,
February 2007 in “The Journal of Clinical Endocrinology and Metabolism” Dutasteride and finasteride may reduce sperm count and volume but don't affect movement or shape; effects are reversible after stopping.
149 citations,
January 2011 in “Nature reviews. Urology” Hormonal interactions, especially involving DHT and estrogen, play a key role in BPH development and treatment.
124 citations,
March 2012 in “JAMA” Testosterone's muscle-building effects do not require its conversion to DHT.
110 citations,
October 2019 in “Translational Andrology and Urology” More men are getting benign prostatic hyperplasia, and there are many treatments, from medication to surgery, with new methods being developed.
110 citations,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
108 citations,
February 2008 in “The Journal of urology/The journal of urology” Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.
98 citations,
February 2013 in “Journal of The American Academy of Dermatology” Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.
98 citations,
August 2004 in “BJU international” Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.
92 citations,
June 2010 in “Journal of The American Academy of Dermatology” Dutasteride 0.5 mg daily improves hair growth safely in men with hair loss.
81 citations,
March 2009 in “Seminars in Cutaneous Medicine and Surgery” Effective hair loss treatment in women requires correct diagnosis and can include medications like minoxidil, antiandrogens, and treatments for underlying conditions like PCOS.
75 citations,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
72 citations,
January 2011 in “Current Pharmaceutical Design” S5αR inhibitors might help treat schizophrenia and other mental disorders but need more research.
72 citations,
April 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
71 citations,
November 2012 in “Expert Opinion on Drug Safety” 5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction and reduced sexual desire, sometimes lasting after stopping the drug.
69 citations,
August 2008 in “Journal of The European Academy of Dermatology and Venereology” Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.
66 citations,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
66 citations,
June 2013 in “Journal of Dermatological Treatment” Finasteride and dutasteride effectively treat hair loss, but may cause side effects like sexual dysfunction and depression.
64 citations,
June 2009 in “Journal of The American Academy of Dermatology” Oral dutasteride can potentially treat frontal fibrosing alopecia in postmenopausal women, with some patients showing disease arrest and hair regrowth.
58 citations,
March 2006 in “Current topics in medicinal chemistry” Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
57 citations,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
52 citations,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
51 citations,
August 2021 in “Turkish Journal of Medical Sciences” As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.
51 citations,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.